Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
Company Details
- Employees
- 78
- Founded
- -
- Address
- Boston, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.a9oncology.com
- Keywords
- Radiopharmaceuticals, Nuclear Medicine, PET Imaging, Cancer, Radiotherapy, Clinical Trials, Biotechnology.
- HQ
- Boston, Massachusetts
Alpha-9 Oncology Questions
Alpha-9 Oncology's website is http://www.a9oncology.com
Alpha-9 Oncology's LinkedIn profile is https://www.linkedin.com/company/a9oncology
Alpha-9 Oncology has
78 employees.
View email and phone details for 78
employees at Alpha-9 Oncology.
Alpha-9 Oncology's industry is
Biotechnology Research
Alpha-9 Oncology's top competitors are
Aspect Biosystems,
Abdera Therapeutics,
Zip,
Rad Ai,
Tennr,
Aktis Oncology,
Seaport Therapeutics,
Zymeworks Inc.,
Infinitus Systems, Inc.,
Abcellera.
Alpha-9 Oncology's categories are Biotechnology Research
Alpha-9 Oncology's founding year is 2019
